Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly EPS (Basic) of $0.32 for Q1 2026, up 65.56% year-on-year from $0.19 in Q1 2025, and down 22.03% on a QoQ basis from $0.41 in Q4 2025.
Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported EPS (Basic) for 18 consecutive years, with $0.32 the latest figure, recorded in Q1 2026.
- Quarterly EPS (Basic) rose 65.56% year-over-year to $0.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.34 (up 215.47% YoY) and the FY2025 annual result came in at $1.23, up 170.71% from the prior year.
- EPS (Basic) fell to $0.32 in Q1 2026 per TEVA's latest filing, from $0.41 in the prior quarter.
- Over the last five years, EPS (Basic) for TEVA reached as high as $0.46 in Q1 2024 and fell as low as -$1.61 in Q4 2023.
- A 5-year average of -$0.25 and a median of -$0.23 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) sank 1278.01% — and 2024, when it surged 303.68%.
- Year by year, EPS (Basic) stood at -$1.2 in 2022, then plunged by 33.55% to -$1.61 in 2023, then soared by 84.85% to -$0.24 in 2024, then surged by 268.82% to $0.41 in 2025, then slipped by 22.03% to $0.32 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered $0.32, $0.41, and $0.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.32 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.42 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.49 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.32 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.15 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.97 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.11 |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -0.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.32 |
| Dec 31, 2025 | 0.41 |
| Sep 30, 2025 | 0.38 |
| Jun 30, 2025 | 0.24 |
| Mar 31, 2025 | 0.19 |
| Dec 31, 2024 | -0.24 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | -0.77 |
| Mar 31, 2024 | 0.46 |
| Dec 31, 2023 | -1.61 |
| Sep 30, 2023 | 0.07 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -0.23 |
| Dec 31, 2022 | -1.20 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.88 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | 0.28 |
| Jun 30, 2021 | 0.19 |